<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054834</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hLL2-14</org_study_id>
    <nct_id>NCT00054834</nct_id>
  </id_info>
  <brief_title>Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in&#xD;
      the treatment of Non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>March 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>27</enrollment>
  <condition>Non-Hodgkins Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hLL2 (epratuzumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease Characteristics:&#xD;
&#xD;
          -  Patients with a documented histologic or cytologic diagnosis of B-cell NHL.&#xD;
&#xD;
          -  Patients who have failed at least one regimen of chemotherapy and are not eligible for&#xD;
             any alternate therapies of higher therapeutic priority.&#xD;
&#xD;
          -  Patients with at least one measurable tumor site &gt; 1.5 cm in at least one dimension.&#xD;
&#xD;
        Prior/Concurrent Therapy:&#xD;
&#xD;
          -  Chemotherapy: Patients must have failed standard therapy or are not eligible for any&#xD;
             alternate therapies of higher therapeutic priority.&#xD;
&#xD;
          -  Biologic Therapy: Patients who have received human or humanized monoclonal antibodies&#xD;
             will be eligible provided pre-study evaluations demonstrate no significant reactivity&#xD;
             with hLL2 IgG (i.e., HAHA).&#xD;
&#xD;
          -  Radiotherapy: No prior radiation therapy to &gt;25% of the bone marrow. No prior&#xD;
             radiation to maximal tolerable levels for any critical organ (e.g., 2,000 cGy for the&#xD;
             lungs and kidneys). Patients who have had whole pelvic irradiation are not eligible.&#xD;
&#xD;
        Patient Characteristics/Inclusion Criteria:&#xD;
&#xD;
          -  Age Range: Male or Female at least 18 years of age&#xD;
&#xD;
          -  Performance Status: Patients with a Karnofsky performance status &gt; 60% (or equivalent,&#xD;
             ECOG 0-2) and expected survival of at least 12 weeks.&#xD;
&#xD;
          -  Hematopoietic: Hemoglobin &gt; 10 g/dL; ANC &gt; 1.5x10^9/L; Platelets &gt; 100x10^9/L;&#xD;
&#xD;
          -  Hepatic: Serum bilirubin &lt; 2.0 mg/dL; AST and ALT &lt; 2 x ULN w/o liver metastases or &lt;5&#xD;
             x ULN w/liver metastases&#xD;
&#xD;
          -  Renal: Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Cardiovascular: Patients with LVEF &gt;/= 50% by MUGA or 2D-ECHO.&#xD;
&#xD;
          -  Pulmonary: Patients with DFCO and FEV1 &gt;/= 60% by required Pulmonary Function Tests.&#xD;
&#xD;
          -  Other: Patients agreeing to use a medically effective method of contraception while&#xD;
             enrolled in the study. A pregnancy test will be performed on each premenopausal female&#xD;
             of childbearing potential immediately prior to entry into the study. Patients able to&#xD;
             understand and give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>February 11, 2003</study_first_submitted>
  <study_first_submitted_qc>February 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2003</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

